[
  {
    "ts": null,
    "headline": "Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?",
    "summary": "Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.",
    "url": "https://finnhub.io/api/news?id=41acb18718b4d62fe969919f54f9213b7b1a28266bf32db064dfd46afcfcf210",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757016000,
      "headline": "Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?",
      "id": 136641768,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.",
      "url": "https://finnhub.io/api/news?id=41acb18718b4d62fe969919f54f9213b7b1a28266bf32db064dfd46afcfcf210"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr.’s Operation Warped Memory",
    "summary": "RFK Jr.’s Operation Warped Memory",
    "url": "https://finnhub.io/api/news?id=552bc5cd6b70816624ad8691132947a5755012281e17a65d6b59249a39588d90",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757011140,
      "headline": "RFK Jr.’s Operation Warped Memory",
      "id": 136715138,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "RFK Jr.’s Operation Warped Memory",
      "url": "https://finnhub.io/api/news?id=552bc5cd6b70816624ad8691132947a5755012281e17a65d6b59249a39588d90"
    }
  },
  {
    "ts": null,
    "headline": "Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer",
    "summary": "The Australia Acute Respiratory Distress Syndrome (ARDS) Market is forecasted to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, with a CAGR of 6.78%. Key drivers include a rising incidence of respiratory diseases, ICU admissions, and technological innovations. Growing awareness of post-COVID lung damage and an aging population further propel demand. Diagnostic and treatment advancements, such as the VitalFlow ECMO System by Medtronic, enhance patient outcomes. Government inves",
    "url": "https://finnhub.io/api/news?id=0124393ccb36eeb8291d3e6b7bd4f6272f11f4b748de403052e6727dbb81deb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757001600,
      "headline": "Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer",
      "id": 136642156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Australia Acute Respiratory Distress Syndrome (ARDS) Market is forecasted to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, with a CAGR of 6.78%. Key drivers include a rising incidence of respiratory diseases, ICU admissions, and technological innovations. Growing awareness of post-COVID lung damage and an aging population further propel demand. Diagnostic and treatment advancements, such as the VitalFlow ECMO System by Medtronic, enhance patient outcomes. Government inves",
      "url": "https://finnhub.io/api/news?id=0124393ccb36eeb8291d3e6b7bd4f6272f11f4b748de403052e6727dbb81deb3"
    }
  },
  {
    "ts": null,
    "headline": "Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors",
    "summary": "BOULDER, Colo., September 04, 2025--Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.",
    "url": "https://finnhub.io/api/news?id=8dfaf59caf98d7f367cb425931200b3371f73415da613fc490f94620373c357d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756990800,
      "headline": "Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors",
      "id": 136642157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BOULDER, Colo., September 04, 2025--Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.",
      "url": "https://finnhub.io/api/news?id=8dfaf59caf98d7f367cb425931200b3371f73415da613fc490f94620373c357d"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy With Less Than $50",
    "summary": "These stocks are cheap in more ways than one.",
    "url": "https://finnhub.io/api/news?id=97c3c62d1edeefc351005a04053c765bcb576513dbc32a8ff9c6cb39c16cef37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756990380,
      "headline": "2 Top Dividend Stocks to Buy With Less Than $50",
      "id": 136642158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These stocks are cheap in more ways than one.",
      "url": "https://finnhub.io/api/news?id=97c3c62d1edeefc351005a04053c765bcb576513dbc32a8ff9c6cb39c16cef37"
    }
  },
  {
    "ts": null,
    "headline": "3 Things You Need to Know if You Buy Pfizer Today",
    "summary": "Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?",
    "url": "https://finnhub.io/api/news?id=2213766ccce6b9991bf12bc13becc1057b10ad016cb0cd3e8c42d37379899bca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756986300,
      "headline": "3 Things You Need to Know if You Buy Pfizer Today",
      "id": 136641988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?",
      "url": "https://finnhub.io/api/news?id=2213766ccce6b9991bf12bc13becc1057b10ad016cb0cd3e8c42d37379899bca"
    }
  }
]